Related Experiment Video

Updated: Jun 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Adjuvant and neoadjuvant drug therapy for prostate cancer]

K Miller1, M Lein, M Schostak

  • 1Klinik und Hochschulambulanz für Urologie, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Deutschland. kurt.miller@charite.de

Der Urologe. Ausg. A
|September 25, 2008
PubMed

Insights

Neoadjuvant and adjuvant hormone therapy for prostate cancer shows limited benefit before surgery but can be considered after radical prostatectomy for specific cases. Long-term adjuvant therapy is recommended for high-risk patients undergoing radiotherapy.

Area of Science:

  • Oncology
  • Urology
  • Endocrinology

Context:

  • Neoadjuvant and adjuvant therapies aim to eradicate micrometastases in various cancers, but carry risks of side effects and overtreatment.
  • Hormone therapy, specifically LHRH analogs and bicalutamide, has been investigated for prostate cancer management.

Purpose:

  • To evaluate the efficacy and provide recommendations for neoadjuvant and adjuvant hormone therapy in prostate cancer treatment.
  • To guide clinical decision-making regarding the use of hormone therapy in different stages of prostate cancer.

Summary:

  • No current indication for neoadjuvant hormone therapy before radical prostatectomy.
  • Adjuvant LHRH analogs post-prostatectomy for node-positive tumors warrant consideration against early treatment triggers.
  • Adjuvant bicalutamide for locally advanced tumors improves progression-free survival, though direct comparison with early treatment is lacking.
  • Neoadjuvant LHRH analogs (2 months) before radiotherapy benefit locally advanced, low-risk (Gleason <7) tumors.
  • Long-term (2-3 years) adjuvant LHRH analogs are indicated for high-risk prostate cancer patients.

Impact:

  • Provides evidence-based recommendations for optimizing hormone therapy use in prostate cancer.
  • Helps clinicians balance the benefits and risks of adjuvant and neoadjuvant strategies.
  • Informs treatment decisions for patients with localized, locally advanced, and node-positive prostate cancer.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...